Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May-Jun;29(3):152-159.
doi: 10.1097/PPO.0000000000000655.

The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances

Michael P Randall  1 , Amy E DeZern  2
Affiliations
Review

The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances

Michael P Randall et al. Cancer J. 2023 May-Jun.

Abstract

The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematologic neoplasms with varied natural histories and prognoses. Specific to this review, treatment of low-risk MDS most often focuses on improving quality of life by correcting cytopenias, as opposed to urgent disease modification to avoid acute myeloid leukemia. These treatments include transfusion support with iron chelation when necessary, growth factors including novel maturation agents such as luspatercept, lenalidomide for del(5q) disease, and, increasingly, low-dose hypomethylating agents. Recent advances in the understanding of the genetic lesions that drive MDS have prompted a reassessment of how low-risk disease is defined and helped to identify a subset of low-risk MDS patients who may benefit from a more aggressive treatment paradigm, including hematopoietic stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: A.E.D. disclosed that she has received consulting fees from Geron, Bristol-Myers Squibb, Novartis, CTI Biopharma, Sobi, and Gilead.

Similar articles

See all similar articles

Cited by

References

    1. Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358–1374. doi:10.1056/NEJMra1904794. - DOI
    1. Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937–944. doi:10.1007/s00277-016-2649-3. - DOI
    1. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. doi:10.1182/blood.2022015850. - DOI
    1. Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020;367:1449–1454. doi:10.1126/science.aay9333. - DOI
    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–1719. doi:10.1038/s41375-022-01613-1. - DOI

MeSH terms